目的:探讨和血明目片对视网膜静脉阻塞性眼底出血临床治疗的疗效及可行性。方法:2006-09/2009-09我院收治的72例72眼视网膜静脉阻塞性眼底出血的患者,随机分成两组,分别给予治疗,Ⅰ组为和血明目片(38例38眼);Ⅱ组为复方血栓通胶囊(34例34眼)。疗效判定标准:(1)治愈:最佳矫正视力恢复到出血前病例记录或患者陈诉的视力水平;(2)显效:治疗后最佳矫正视力较视网膜静脉阻塞性眼底出血就诊时的病例记录提高3行以上;(3)有效:治疗后最佳矫正视力较视网膜静脉阻塞性眼底出血就诊时的病例记录提高1行以上;(4)无效:治疗后最佳矫正视力较视网膜静脉阻塞性眼底出血就诊时的病例记录未提高或下降。结果:随访6mo后,72眼观察病例中,最佳矫正视力68眼有不同程度提高,总有效率94%;显效率31%(72眼,22眼显效),治愈率10%(72眼,7眼治愈)。其中,Ⅰ组总有效率为97%(38眼,37眼有效);显效率39%(38眼,15眼显效),治愈率13%(38眼,5眼治愈)。Ⅱ组总有效率为91%(34眼,31眼有效);显效率21%(34眼,7眼显效),治愈率7%(34眼,2眼治愈)。Ⅰ组与Ⅱ组总有效率差异无统计学意义(P=0.341),显效率差异有统计学意义(P<0.05)。结论:和血明目片治疗静脉栓塞性眼底出血临床有效,能明显消除积血,改善患者视力。

·AIM:To evaluate the effects of hexuemingmu tablets for retinal hemorrhage caused by retinal vein occlusion.·METHODS:A randomized controlled study was performed on 72 patients(72 eyes).Patients were divided into 2 groups randomly:38 patients in I group(hexuemingmu,38 eyes);34 patients in Ⅱgroup(fufangxueshuantong,34 eyes).The standard of effectiveness:Cure:best-corrected visual acuity(BCVA)recovered to the statements before the hemorrhage the case recorded or the level patients expressed,retinal hemorrhage,edema completely absorbed;Markedly:BCVA improved more than three rows compared to the one the case recorded when registered.Effective:BCVA only improved more than one row;Invalid:BCVA is not improved or gets worse.·RESULTS:After six months,BCVA of 68 eyes was improved,the total effective rate was 94%,marked improvement rate was 31%(22 eyes).Cure rate was 10%(7 eyes).In I group:the total effective rate was 97%(37 eyes),marked improvement rate was 39%(15 eyes).Cure rate was 13%(5 eyes).In Ⅱ group:the total effective rate was 91%(31 eyes),marked improvement rate was 21%(7 eyes),cure rate was 7%(2 eyes),the rate of effectiveness of two groups didn’t show statistical difference(P=0.341),while the rate of marked improvement of two groups showed statistical difference(P<0.05)。·CONCLUSION:Hexuemingmu tablets is an effective drug for retinal hemorrhage caused by retinal vein occlusion.It’s helpful in eliminating the hemorrhage and improving the patient’s BCVA.·

R276.7